Peter Ellmark

Chief Scientific Officer

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Peter Ellmark is the Chief Scientific Officer at Alligator Bioscience AB in Sweden. His research focuses on cancer immunotherapy, particularly in the development of CD40 agonists and bispecific antibodies. Recent publications include studies on antigenic peptide delivery systems, phase I trials of novel cancer treatments, and the immunological responses of T cell populations in various cancer types.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (4)

Kristina Lundberg

SWEDEN

View details

Mats Ohlin

Lund University

SWEDEN

View details

Henrik Lilljebjörn

Lund University

SWEDEN

View details

Christina Alexandra Sakellariou

Lund University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Peter Ellmark

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform

First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes

Next-generation CD40 agonists for cancer immunotherapy

ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies

The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.

Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

CD137 (4-1BB) costimulation of CD8<sup>+</sup> T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

Collaborators (4)

Kristina Lundberg

Mats Ohlin

Henrik Lilljebjörn

Christina Alexandra Sakellariou

Make your next move.